Flu vaccine for 2016-17 season not considered effective in the over 65s age group

Flu vaccine for 2016-17 season not considered effective in the over 65s age group

September 6 2017 Provisional figures for vaccine effectiveness in the 2016-17 flu season have...

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

September 4 2017 Prescription strength doses of ibuprofen are associated with increased blood...

Avoid oral corticosteroids in chest infections in adults unless asthmatic

Avoid oral corticosteroids in chest infections in adults unless asthmatic

August 31 2017 Doctors are being advised not to prescribe prednisolone or other oral...

Recall issued affecting NovoPen Echo and NovoPen 5 insulin pens

Recall issued affecting NovoPen Echo and NovoPen 5 insulin pens

August 24 2017 A recall affecting 53 batches of Novo Nordisk’s NovoPen Echo and 34 batches...

NICE updates guidance on fever in young children

NICE updates guidance on fever in young children

August 14 2017 A number of changes have been made to the NICE guidelines and assessing and...

  • Flu vaccine for 2016-17 season not considered effective in the over 65s age group

    Flu vaccine for 2016-17 season not considered effective in the over 65s age group

    Wednesday, 06 September 2017 16:53
  • Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Study finds ibuprofen is linked to blood pressure rise in arthritis patients at cardiovascular risk

    Monday, 04 September 2017 15:47
  • Avoid oral corticosteroids in chest infections in adults unless asthmatic

    Avoid oral corticosteroids in chest infections in adults unless asthmatic

    Thursday, 31 August 2017 13:35
  • Recall issued affecting NovoPen Echo and NovoPen 5 insulin pens

    Recall issued affecting NovoPen Echo and NovoPen 5 insulin pens

    Thursday, 24 August 2017 13:50
  • NICE updates guidance on fever in young children

    NICE updates guidance on fever in young children

    Monday, 14 August 2017 09:59

drugalertJune 29 2016

Adempas (riociguat) should not be used in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonia or PH-IIP, the European Medicines Agency has warned.

Although the drug is not authorised for use in PH-IIP patients, the EMA has issued the recommendation following the early termination of a phase II clinical trial, RISE-IIP, investigating the effects of Adempas in this patient population.

“Preliminary results showed an increased number of deaths and serious adverse events, including breathing problems and lung infections, with Adempas compared with placebo. The available data do not indicate a clinically significant benefit from Adempas treatment in these patients,” said the EMA’s announcement, published on June 24.

The trial had been assessing the medicine in 145 PH-IIP patients, with the primary endpoint being the change in the 6-minute walking distance test after 6 months of treatment. “At the time of the interim assessment leading to the termination of the trial, 21 deaths had been observed, 17 patients taking Adempas and 4 patients taking placebo. Serious adverse events, which were mostly respiratory disease or lung infections, were also higher among patients taking Adempas.”

EMA is advising health professionals that “if any patients with PH-IIP are being treated with Adempas, this treatment should be discontinued and the patient’s clinical status carefully monitored.” A contraindication will also be included in prescribing information, and EMA will be issuing a letter to health professionals. 

It has also stated that Adempas continues to have a positive benefit-risk balance for its authorised uses.

The product’s indications in the UK are:

  • treating adults with WHO Functional Class (FC) II to III with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), or persistent or recurrent CTEPH after surgical treatment, to improve exercise capacity
  • as monotherapy or in combination with endothelin receptor antagonists for adults with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.

Links:

EMA announcement

Adempas SPC on eMC

Clinical News

September 21 2017 A new study has identified a wide variation in referral practice for suspected cancers by GPs.
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...